Company intelligence / Profile preview

OCCAM Immune

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Occam Immune is a South San Francisco-based biotechnology company dedicated to the discovery and development of novel immunotherapies for oncology and inflammatory diseases. Founded by Dr. David S. Johnson, the former CEO of GigaGen, the company utilizes advanced high-throughput screening and immune profiling technologies to identify high-impact therapeutic targets. Occam Immune's approach is centered on simplifying the complexity of the immune response to design more precise and potent biologics, including monoclonal and bispecific antibodies. The company leverages a proprietary platform to analyze the immune repertoire and identify rare, highly effective antibodies. Currently in the pre-clinical stage, Occam Immune is advancing a pipeline of candidates aimed at overcoming resistance to existing checkpoint inhibitors and treating autoimmune conditions.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodyBispecific monoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on OCCAM Immune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCCAM Immune.

Explore the full profile